OPKO Health, Inc. (OPK)
USD 1.42
(0.35%)
USD 1.42
(0.35%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 863.49 Million USD | -14.01% |
| 2022 | 1 Billion USD | -43.42% |
| 2021 | 1.77 Billion USD | 23.64% |
| 2020 | 1.43 Billion USD | 59.15% |
| 2019 | 901.9 Million USD | -8.93% |
| 2018 | 990.3 Million USD | 2.51% |
| 2017 | 966 Million USD | -20.93% |
| 2016 | 1.22 Billion USD | 148.46% |
| 2015 | 491.7 Million USD | 439.74% |
| 2014 | 91.1 Million USD | -5.63% |
| 2013 | 96.53 Million USD | 105.19% |
| 2012 | 47.04 Million USD | 68.14% |
| 2011 | 27.97 Million USD | -1.81% |
| 2010 | 28.49 Million USD | 116.73% |
| 2009 | 13.14 Million USD | 39.27% |
| 2008 | 9.44 Million USD | 1014.52% |
| 2007 | 847 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 13 Thousand USD | -97.69% |
| 2002 | 562 Thousand USD | -57.84% |
| 2001 | 1.33 Million USD | 54.1% |
| 2000 | 865 Thousand USD | -37.09% |
| 1999 | 1.37 Million USD | 14.58% |
| 1998 | 1.2 Million USD | 1100.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 173.68 Million USD | -4.52% |
| 2024 Q2 | 182.18 Million USD | 4.89% |
| 2023 Q2 | 265.41 Million USD | 11.71% |
| 2023 FY | 863.49 Million USD | -14.01% |
| 2023 Q4 | 181.9 Million USD | 1.85% |
| 2023 Q3 | 178.6 Million USD | -32.71% |
| 2023 Q1 | 237.6 Million USD | 28.16% |
| 2022 Q1 | 329.21 Million USD | -17.96% |
| 2022 FY | 1 Billion USD | -43.42% |
| 2022 Q3 | 179.74 Million USD | -42.0% |
| 2022 Q4 | 185.4 Million USD | 3.15% |
| 2022 Q2 | 309.89 Million USD | -5.87% |
| 2021 Q1 | 545.16 Million USD | 10.22% |
| 2021 Q2 | 442.4 Million USD | -18.85% |
| 2021 Q3 | 385.81 Million USD | -12.79% |
| 2021 Q4 | 401.3 Million USD | 4.01% |
| 2021 FY | 1.77 Billion USD | 23.64% |
| 2020 FY | 1.43 Billion USD | 59.15% |
| 2020 Q4 | 494.6 Million USD | 15.54% |
| 2020 Q2 | 301.2 Million USD | 42.44% |
| 2020 Q3 | 428.06 Million USD | 42.12% |
| 2020 Q1 | 211.46 Million USD | -5.72% |
| 2019 Q3 | 228.77 Million USD | 1.06% |
| 2019 Q1 | 222.5 Million USD | 0.27% |
| 2019 Q2 | 226.36 Million USD | 1.74% |
| 2019 Q4 | 224.3 Million USD | -1.95% |
| 2019 FY | 901.9 Million USD | -8.93% |
| 2018 Q1 | 254.9 Million USD | 31.6% |
| 2018 Q3 | 249.81 Million USD | -5.26% |
| 2018 FY | 990.3 Million USD | 2.51% |
| 2018 Q4 | 221.9 Million USD | -11.17% |
| 2018 Q2 | 263.68 Million USD | 3.45% |
| 2017 Q3 | 263.49 Million USD | -16.14% |
| 2017 FY | 966 Million USD | -20.93% |
| 2017 Q4 | 193.7 Million USD | -26.49% |
| 2017 Q2 | 314.21 Million USD | 6.12% |
| 2017 Q1 | 296.09 Million USD | 7.48% |
| 2016 Q4 | 275.5 Million USD | -7.55% |
| 2016 Q3 | 298 Million USD | -16.55% |
| 2016 Q1 | 291.03 Million USD | 5.37% |
| 2016 Q2 | 357.1 Million USD | 22.7% |
| 2016 FY | 1.22 Billion USD | 148.46% |
| 2015 Q2 | 42.42 Million USD | 41.04% |
| 2015 Q4 | 276.2 Million USD | 93.1% |
| 2015 FY | 491.7 Million USD | 439.74% |
| 2015 Q1 | 30.08 Million USD | 17.98% |
| 2015 Q3 | 143.03 Million USD | 237.11% |
| 2014 Q2 | 23.54 Million USD | 5.71% |
| 2014 FY | 91.1 Million USD | -5.63% |
| 2014 Q4 | 25.5 Million USD | 28.96% |
| 2014 Q1 | 22.27 Million USD | 7.65% |
| 2014 Q3 | 19.77 Million USD | -16.02% |
| 2013 Q2 | 23.82 Million USD | -24.08% |
| 2013 Q3 | 20.64 Million USD | -13.35% |
| 2013 Q1 | 31.37 Million USD | 92.95% |
| 2013 FY | 96.53 Million USD | 105.19% |
| 2013 Q4 | 20.69 Million USD | 0.25% |
| 2012 Q1 | 8.77 Million USD | 51.48% |
| 2012 Q2 | 10.21 Million USD | 16.34% |
| 2012 Q3 | 11.79 Million USD | 15.51% |
| 2012 FY | 47.04 Million USD | 68.14% |
| 2012 Q4 | 16.26 Million USD | 37.86% |
| 2011 Q3 | 6.8 Million USD | -32.88% |
| 2011 FY | 27.97 Million USD | -1.81% |
| 2011 Q4 | 5.79 Million USD | -14.88% |
| 2011 Q1 | 8.64 Million USD | -37.8% |
| 2011 Q2 | 10.14 Million USD | 17.28% |
| 2010 Q2 | 7.45 Million USD | -5.89% |
| 2010 Q1 | 7.92 Million USD | 13.2% |
| 2010 FY | 28.49 Million USD | 116.73% |
| 2010 Q4 | 13.9 Million USD | 82.97% |
| 2010 Q3 | 7.59 Million USD | 1.93% |
| 2009 Q3 | 1.5 Million USD | -36.05% |
| 2009 Q4 | 6.99 Million USD | 366.22% |
| 2009 Q1 | 2.3 Million USD | 36.4% |
| 2009 FY | 13.14 Million USD | 39.27% |
| 2009 Q2 | 2.34 Million USD | 2.0% |
| 2008 Q4 | 1.68 Million USD | -58.35% |
| 2008 FY | 9.44 Million USD | 1014.52% |
| 2008 Q1 | 2.82 Million USD | 233.41% |
| 2008 Q2 | 879 Thousand USD | -68.87% |
| 2008 Q3 | 4.05 Million USD | 360.75% |
| 2007 Q1 | 210 Thousand USD | 0.0% |
| 2007 Q4 | 847 Thousand USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 FY | 847 Thousand USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | 15 Thousand USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | 13 Thousand USD | 116.67% |
| 2003 FY | 13 Thousand USD | -97.69% |
| 2002 Q4 | 6000.00 USD | 0.0% |
| 2002 Q2 | 222 Thousand USD | -33.33% |
| 2002 Q1 | 333 Thousand USD | 0.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 FY | 562 Thousand USD | -57.84% |
| 2001 Q3 | 333 Thousand USD | -0.3% |
| 2001 FY | 1.33 Million USD | 54.1% |
| 2001 Q1 | 333 Thousand USD | 200.0% |
| 2001 Q2 | 334 Thousand USD | 0.3% |
| 2001 Q4 | 333 Thousand USD | 0.0% |
| 2000 Q1 | 344 Thousand USD | -40.17% |
| 2000 Q4 | 111 Thousand USD | 65.67% |
| 2000 Q3 | 67 Thousand USD | -80.47% |
| 2000 Q2 | 343 Thousand USD | -0.29% |
| 2000 FY | 865 Thousand USD | -37.09% |
| 1999 Q2 | 300 Thousand USD | 50.0% |
| 1999 Q1 | 200 Thousand USD | 0.0% |
| 1999 FY | 1.37 Million USD | 14.58% |
| 1999 Q3 | 300 Thousand USD | 0.0% |
| 1999 Q4 | 575 Thousand USD | 91.67% |
| 1998 FY | 1.2 Million USD | 1100.0% |
| 1998 Q3 | 200 Thousand USD | -75.0% |
| 1998 Q2 | 800 Thousand USD | 700.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1998 Q4 | 200 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q4 | - USD | -100.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aspira Women's Health Inc. | 9.15 Million USD | -9332.98% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -33996.558% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -27649.221% |
| Standard BioTools Inc. | 106.34 Million USD | -712.013% |
| Inotiv, Inc. | 572.42 Million USD | -50.849% |
| Prenetics Global Limited | 21.74 Million USD | -3871.429% |
| Neuronetics, Inc. | 71.34 Million USD | -1110.258% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1785.978% |
| Castle Biosciences, Inc. | 219.78 Million USD | -292.876% |
| Psychemedics Corporation | 22.09 Million USD | -3807.571% |
| RadNet, Inc. | 1.61 Billion USD | 46.587% |
| Exact Sciences Corporation | 2.49 Billion USD | 65.457% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 76.413% |
| iSpecimen Inc. | 9.92 Million USD | -8597.411% |
| OpGen, Inc. | 3.41 Million USD | -25160.801% |
| Exagen Inc. | 52.54 Million USD | -1543.25% |
| Bionano Genomics, Inc. | 36.11 Million USD | -2290.893% |
| CareDx, Inc | 280.32 Million USD | -208.035% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | -175.9% |
| Guardant Health, Inc. | 563.94 Million USD | -53.116% |
| Biodesix, Inc. | 49.08 Million USD | -1659.111% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -8737.5% |
| Precipio, Inc. | 15.19 Million USD | -5582.01% |
| Natera, Inc. | 1.08 Billion USD | 20.237% |
| Fulgent Genetics, Inc. | 289.21 Million USD | -198.567% |
| Sera Prognostics, Inc. | 306 Thousand USD | -282087.908% |
| 23andMe Holding Co. | 219.63 Million USD | -293.145% |
| Personalis, Inc. | 73.48 Million USD | -1075.127% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -2663.272% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -6359.687% |
| T2 Biosystems, Inc. | 7.19 Million USD | -11904.657% |
| Neogen Corporation | 924.22 Million USD | 6.571% |
| Myriad Genetics, Inc. | 678.4 Million USD | -27.284% |
| ICON Public Limited Company | 8.12 Billion USD | 89.366% |
| NeoGenomics, Inc. | 591.64 Million USD | -45.949% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1785.978% |
| MDxHealth SA | 70.19 Million USD | -1130.173% |
| Prenetics Global Limited | 21.74 Million USD | -3871.429% |
| Illumina, Inc. | 4.5 Billion USD | 80.828% |
| DarioHealth Corp. | 20.35 Million USD | -4142.802% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 54.212% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -96328.28% |
| Trinity Biotech plc | 56.83 Million USD | -1419.382% |
| Sotera Health Company | 1.04 Billion USD | 17.707% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -33996.558% |